BVS
Bioventus Inc. NASDAQ Listed Feb 11, 2021$10.64
Mkt Cap $720.0M
52w Low $5.81
88.9% of range
52w High $11.25
50d MA $9.33
200d MA $7.83
P/E (TTM)
29.7x
EV/EBITDA
7.2x
P/B
3.0x
Debt/Equity
1.9x
ROE
15.1%
P/FCF
6.9x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$9.33
200d MA
$7.83
Avg Volume
403.7K
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
4721 EMPEROR BOULEVARD, SUITE 100 · DURHAM, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | BMO | 0.22 | 0.24 | +9.1% | 9.10 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% | — |
| Nov 4, 2025 | BMO | 0.21 | 0.15 | -30.2% | 7.55 | -0.7% | -2.3% | +1.4% | -0.4% | +0.5% | +2.8% | — |
| Aug 6, 2025 | BMO | 0.22 | 0.21 | -4.5% | 7.29 | -0.3% | -4.9% | -0.1% | +0.1% | +5.5% | +3.0% | — |
| May 6, 2025 | BMO | 0.06 | 0.08 | +33.3% | 6.20 | +0.5% | +6.3% | +3.2% | -1.8% | +0.9% | -3.0% | — |
| Mar 11, 2025 | BMO | 0.08 | 0.15 | +87.5% | 10.80 | +0.1% | -6.8% | -4.6% | +0.0% | +2.0% | -2.4% | — |
| Nov 5, 2024 | BMO | 0.06 | 0.06 | +0.0% | 11.48 | +4.5% | -1.7% | -0.4% | +5.2% | +5.2% | -4.8% | — |
| Aug 6, 2024 | BMO | 0.07 | 0.19 | +171.4% | 8.09 | +3.3% | -7.8% | +1.9% | -0.1% | -0.4% | +4.5% | — |
| May 7, 2024 | BMO | -0.05 | 0.07 | +240.0% | 5.12 | +5.5% | -1.6% | +8.3% | -1.1% | +5.9% | +4.7% | — |
| Mar 12, 2024 | BMO | 0.06 | 0.07 | +16.7% | 5.60 | +1.8% | -5.5% | -1.9% | +5.0% | +0.7% | -1.6% | — |
| Nov 7, 2023 | BMO | 0.06 | 0.05 | -16.7% | 3.61 | -0.6% | +5.5% | -7.6% | +0.0% | +5.1% | +1.6% | — |
| Aug 8, 2023 | BMO | 0.03 | 0.14 | +366.7% | 3.88 | +6.7% | +5.4% | +11.7% | -1.1% | +4.9% | +4.2% | — |
| May 16, 2023 | BMO | -0.11 | -0.26 | -136.4% | 1.20 | +0.0% | +9.2% | +11.5% | +33.6% | +7.2% | +16.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Barrington Research | Maintains | Outperform → Outperform | — | $9.10 | $8.96 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% |
| Mar 6 | Craig-Hallum | Maintains | Buy → Buy | — | $9.10 | $8.96 | -1.5% | -7.6% | +2.4% | +2.9% | +0.5% | -3.4% |
| Mar 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.61 | $9.54 | -0.7% | +2.0% | -2.4% | +3.9% | -1.9% | -0.9% |
| Dec 17 | JP Morgan | Upgrade | Underweight → Neutral | — | $11.15 | $11.40 | +2.2% | +0.0% | -4.8% | -0.8% | +1.4% | -0.2% |
| Nov 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.48 | $12.00 | +4.5% | -1.7% | -0.4% | +5.2% | +5.2% | -4.8% |
| Sep 27 | Craig-Hallum | Maintains | Buy → Buy | — | $11.05 | $11.52 | +4.3% | +5.3% | +2.7% | -1.3% | -0.1% | -0.9% |
| Aug 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.56 | $7.57 | +0.1% | +4.5% | +1.3% | +3.5% | +4.8% | -7.8% |
| Aug 7 | Craig-Hallum | Maintains | Buy → Buy | — | $8.09 | $8.36 | +3.3% | -7.8% | +1.9% | -0.1% | -0.4% | +4.5% |
| May 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.12 | $5.40 | +5.5% | -1.6% | +8.3% | -1.1% | +5.9% | +4.7% |
| Mar 13 | Craig-Hallum | Maintains | Buy → Buy | — | $5.60 | $5.70 | +1.8% | -5.5% | -1.9% | +5.0% | +0.7% | -1.6% |
| Dec 7 | Canaccord Genuity | Upgrade | Hold → Buy | — | $4.52 | $4.80 | +6.2% | +13.1% | -1.4% | -1.8% | -2.0% | -1.0% |
| Apr 3 | Craig-Hallum | Maintains | Hold → Hold | — | $1.07 | $1.09 | +1.9% | +5.6% | -2.7% | +12.7% | +5.6% | -11.5% |
| Nov 30 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.88 | $1.86 | -1.1% | +3.7% | +11.3% | -1.8% | +5.6% | -2.2% |
| Nov 22 | Craig-Hallum | Downgrade | Buy → Hold | — | $1.88 | $1.82 | -3.2% | -3.7% | +21.0% | +11.9% | -20.4% | -3.6% |
| Nov 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.58 | $2.68 | +3.9% | +25.6% | +2.5% | -5.1% | +4.1% | -9.5% |
| Nov 9 | Canaccord Genuity | Downgrade | Buy → Hold | — | $3.00 | $2.90 | -3.3% | -14.0% | +25.6% | +2.5% | -5.1% | +4.1% |
| Nov 9 | JP Morgan | Downgrade | Overweight → Underweight | — | $3.00 | $2.90 | -3.3% | -14.0% | +25.6% | +2.5% | -5.1% | +4.1% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.95 | $6.83 | -1.7% | -3.5% | -3.7% | -0.3% | -6.4% | +11.1% |
| Sep 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.62 | $7.53 | -1.2% | -2.0% | +5.6% | +2.8% | +4.2% | -3.0% |
| Aug 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.42 | $8.45 | +0.4% | +7.8% | -2.5% | +1.7% | -3.3% | -2.6% |
| May 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.49 | $7.47 | -0.3% | +7.5% | +7.0% | -0.8% | +6.6% | -4.3% |
| Mar 21 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.08 | $13.96 | -0.9% | -2.5% | +0.5% | -6.4% | +0.9% | -0.1% |
| Mar 15 | Craig-Hallum | Maintains | Buy → Buy | — | $12.66 | $13.68 | +8.1% | +6.2% | +2.3% | +2.2% | +0.1% | -2.5% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.03 | $14.18 | +1.1% | -0.4% | -9.4% | +6.2% | +2.3% | +2.2% |
| Jul 1 | Goldman Sachs | Downgrade | Buy → Neutral | — | $17.60 | $16.75 | -4.8% | -2.2% | -4.1% | +0.4% | -3.1% | +1.1% |
| Apr 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.82 | $14.99 | +1.1% | -0.3% | +3.0% | -3.2% | -3.0% | -1.5% |
| Mar 8 | Goldman Sachs | Maintains | Buy → Buy | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | JP Morgan | Maintains | Overweight → Overweight | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
| Mar 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.49 | $12.01 | +4.5% | +0.2% | +7.2% | +1.5% | +11.8% | +2.5% |
No insider trades available.
8-K · 2.02
!! High
Bioventus Inc. -- 8-K 2.02: Earnings Results
Bioventus Inc. released earnings results that investors can review in the attached press release for insight into the company's operational performance and financial condition.
May 6
8-K
Bioventus Inc. -- 8-K Filing
Bioventus reported strong Q4 2025 results with above-market growth and margin improvements, while providing 2026 guidance after strengthening its portfolio and balance sheet.
Mar 5
Data updated apr 24, 2026 11:17pm
· Source: massive.com